CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
MK-3475 (neoadjuvant) +6 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02296684
NCT02296684Phase 2Completed
CompareCT.gov

Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine·interventional·Posted Nov 20, 2014·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating MK-3475 (neoadjuvant), Surgery, and 5 other interventions for Cancer of Head and Neck and 5 related conditions. Completed, enrolled 67 participants across 3 sites.

Detailed Summary

The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 20, 2014
Enrollment StartMar 25, 2015
Primary CompletionApr 5, 2022
Study CompletionJul 21, 2025
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 11.6 years ago

Interventions

MK-3475 (neoadjuvant)biological

Surgeryprocedure

Standard of care

Intensity modulated radiation therapyradiation

Recommended, standard of care

Image-guided radiation therapyradiation

Recommended, standard of care

Cisplatindrug

Standard of care

MK-3475 (adjuvant)biological

Peripheral bloodprocedure

-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery